Formulation Development of Phase 1-2 Biopharmaceuticals: An Efficient and Timely Approach

Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals

Volumn , Issue , 2010, Pages 147-159

  Warne, Nicholas W ^a  

^a Wyeth BioPharma   (United States)

Author keywords

Excipients utilized for buffering protein solutions; Formulation development of phase 1 2 biopharmaceuticals efficient and timely approach; Formulation performance assessment

Indexed keywords

EID: 84886036378     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470595886.ch6     Document Type: Chapter

References (31)

1. Capelle, M, A. H., Gurny, R., and Arvinte, T. (2007), High throughput screening of protein formulation stability: Practical considerations, Eur. J. Pharm. Biopharm. 65: 131-148.
2. Das, D. (2007), Early stage protein formulation development and use of high throughput screening methods, Proc. AAPS National Biotechnology Conf, June 24-27, 2007, San Diego, CA.
3. FDA (2004), Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products, FDA report, March 2004.
4. Manning, M. C., Patel, K., and Borchardt, R. T. (1989), Stability of protein pharmaceuticals, Pharm. Res. 6: 903-918.
5. Carpenter, J. F., Pikal, M. J., Chang, B. S., and Randolph, T. W. (1997), Rational design of stable lyophilized protein formulations: Some practical advice, Pharm. Res. 14: 969-975.
6. See www.Amevive.com, Astellas Pharma US, Inc., Deerfield, IL 60015.
7. See www.enbrel.com, Amgen, Thousand Oaks, CA 91320 and Wyeth Pharmaceuticals Inc., Philadelphia, PA 19101.
8. See www.herceptin.com, Genentech Inc., South San Francisco, CA 94080-4990.
9. See www.humira.com, Abbott Laboratories, Abbott Park, IL.
10. See www.raptiva.com, Genentech Inc., South San Francisco, CA 94080-4990.
11. See www.remicade.com, Centocor, Inc., Horsham, PA 19044.
12. See www.rituxan.com, Genentech Inc., South San Francisco, CA 94080-4990.
13. See www.rocheusa.com/products/zenapax/, Hoffmann-La Roche Inc.
14. See www.xolair.com, Genentech Inc. and Novartis Pharmaceuticals.
15. Telang, C., Yu, L., and Suryanarayanan, R. (2003), Effective inhibition of mannitol crystallization in frozen solutions by sodium chloride, Pharm. Res. 20: 660-667.
16. Chang, B. S., Kendrick, B. S., and Carpenter, J. F. (1996), Surface-induced denaturation of proteins during freezing and its inhibition by surfactants, J. Pharm. Sci, 85: 1325-1330.
17. ICH (Int. Conf. Harmonization) (2005), ICH Harmonized Tripartate Guideline on Pharmaceutical Development, Q8, Step 4 version dated Nov. 10, 2005.
18. Sarciaux, J.-M., Mansour, S., Hageman, M. J., and Nail, S. L. (1999), Effects of uffer composition and processing conditions on aggregation of bovine IgG during freeze-drying, J. Pharm. Sci, 88: 1354-1361.
19. Anchordoquy, T. J. and Carpenter, J. F. (1996), Polymers protect lactate dehydrogenase during freeze-drying by inhibiting dissociation in the frozen state, Arch. Biochem. Biophys. 332: 231-238.
20. See www.actimmune.com, Intermune Inc., Brisbane, CA 94005.
21. Yim, K. W., Huberty, M. C., Northey, Jr., R. P., and Schrier, J. A. (January 31, 1995), Formulations for Delivery of Osteogenic Proteins, US Patent 5,385,887.
22. See www.leukine.com, Berlex, Seattle, WA 98101.
23. Allison, S. D., Randolph, T. W., Manning, M. C., Middleton, K., Davis, A., and Carpenter, J. F. (1998), Effects of drying methods and additives on structure and function of actin: Mechanisms of dehydration-induced damage and its inhibition, Arch. Biochem. Biophys. 358: 171-181.
24. Farr, G. W. and Heitz, J. R. (1974), Imidazole catalysis of sucrose hydrolysis, J. Dental Res. 53: 516-519.
25. Wang, E. A., Rosen, V., Cordes, P., Hewick, R. M., Kriz, M. J., Luxenberg, D. P., Sibley, B. S., and Wozney, J. M. (1988), Purification and characterization of other distinct boneinducing factors, Proc. Natl. Acad. Sci. USA 85: 9484-9488.
26. Termaat, M. F., Den Boer, F. C., Bakker, F. C., Patka, P., and Haarman, H. J. Th. M. (2005), Bone morphogenetic proteins. Development and clinical efficacy in the treatment of fractures and bone defects, J. Bone Joint Surg. 87: 1367-1378.
27. Abatiello, S. E. and Porter, T. J. (1997), Anion-mediated precipitation of recombinant human bone morphogenetic protein (rhBMP-2) is dependent upon the heparin binding N-terminal region, Proc. Protein Society Meeting, Boston, July 13-16, 1997.
28. Remmele, R. L. Jr. and Gombotz, W. R. (2000), Differential scanning calorimetry: A practical tool for elucidating stability of liquid pharmaceuticals, BioPharm 13: 36-46.
29. Warne, N. W., BMP-2/ACS: Influence of the delivery matrix on the behavior of rhBMP-2, and Proc. Protein Stability Conference, Breckenridge, July 2005.
30. Susi, H. and Byler, D. M. (1983), Protein structure by Fourier transform infrared spectroscopy: Second derivative spectra, Biochem. Biophys. Res. Commun. 115: 391-397.
31. Vidanovic, D., Askrabic, J. M., Stankovic, M., and Poprzen, V. (2003), Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation, Pharmazie 58: 399-404.